27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
We have a poor understanding of whether dementia clusters geographically, how this occurs, and how dementia may relate to socio-demographic factors. 5 key findings →
Participants: 14,746 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
At the end of 2022, 3.7% (92,293/2,483,798) of people aged ≥62 years in Sweden had a dementia diagnosis from specialist care or drug prescriptions and varied from 0.6% in ages 62-69 to 14.8% in ages ≥90. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Previous studies indicate that increased healthcare access through Medicaid expansion and alleviation of socioeconomic stressors via higher minimum wages improved health outcomes. 5 key findings →
Participants: 311 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Among 32,430 individuals (mean age at first hospital encounter 76.6±10.9 years; 59.1% female; 4.2% African American; 5.0% Hispanic), only 16.0% received an MCI diagnosis before their dementia diagnosis. 5 key findings →
Participants: 32,430 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
A rising trend of admission spells was noted from January 2005 to March 2013 (daily average admissions for month rising from over 2000 to over 4000). 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Across both cohorts, individuals with lower SES generally exhibited higher BERs (worse performance) than high SES groups, confirming the presence of bias. 5 key findings →
Participants: 3,041 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
We identified three distinct DP (characterised as 'High Red Meat', 'Low Meat', and 'High Butter') that varied with key sociodemographic, health and functioning measures. 'Low Meat' participants were more advantaged (i.e. higher education and occupational class, and lived in more affluent areas in owned homes), were least disabled, cognitively impaired, and depressed, and were more physically active than those in the other DP. 3 key findings →
Participants: 793 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
We combine the MAX data with Medicare claims to identify hospital admissions, our main outcome variable, and with state and county data on the percent of individuals receiving HCBS versus nursing home care. 3 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Of 1,073 caregivers, 33% reported high baseline strain. 5 key findings →
Participants: 100,000 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Older patients with kidney failure residing in high-disadvantage neighborhoods, particularly Black patients and those in suburban, rural, or small-town areas, had a higher risk of ADRD compared with those in low-disadvantage neighborhoods. 5 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The study has enrolled over 1,600 normal control participants since study inception. 150 original participants continue their participation. 1 key finding →
Design: cohort study Participants: 103 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
We found that ∼25% of donors lived in high deprivation contexts, 52% had at least one incidence of CVD, and the cohort identified as .05). 3 key findings →
Participants: 7,187 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Amyloid-PET demonstrated high sensitivity (100% in year 1, 94.67% in year 4) and a high negative predictive value (100% in year 1, 88.24% in year 4). 5 key findings →
Participants: 145 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Lack of vitamin D is associated with cognitive decline and Alzheimer's disease. 5 key findings →
Design: cross-sectional Participants: 311 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Regardless of method or adjustment, the resulting heritability estimates were highly variable across populations. 5 key findings →
Participants: 7,024 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Compared with men, women had greater amyloid burden (B = 0.05; 95% CI, 0.02-0.07; P < .001), Braak stages III and IV (B = 0.05; 95% CI, 0.02-0.08; P = .003) and Braak stages V and VI (B = 0.09; 95% CI, 0.06-0.12; P < .001) tau burden, and AD signature thickness (B = 0.04; 95% CI, 0.02-0.05; P < .001). 5 key findings →
Design: cross-sectional Participants: 501 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Among 5712 adults (mean [SD] age, 63.47 (8.15) years; unweighted 3663 [53.92%] female), higher ln(ptau-181) was associated with ECog-12 memory (unstandardized β = 0.088; 95% CI, 0.005-0.170). 5 key findings →
Design: cross-sectional Participants: 5,712 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Transcranial direct current stimulation (tDCS) is a promising non-invasive intervention for mild cognitive impairment (MCI). 4 key findings →
Design: longitudinal study Participants: 55 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Four hundred eighty-six participants developed dementia during 37,782 person-years of follow-up. 5 key findings →
Participants: 5,205 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
A recent randomized trial demonstrated clear cerebrospinal-fluid DHA target engagement without detectable improvement in cognition or brain volume over 24 months. 5 key findings →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Significant correlations emerged between higher MEDAS scores and BMI (r = −0.53, p < 0.01), FM% (r = −0.49, p < 0.01), VAT (r = −0.63, p < 0.01), and cIMT (r = −0.88, p < 0.01). 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Social vulnerability indices are increasingly employed as policy and planning instruments for disaster risk reduction. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
DRRLS score of 83.61 ± 16.13, multiple linear regression showed that the patient's monthly individual income, the presence of chronic disease, health beliefs, and social support were independent influences on their dementia risk reduction lifestyle. 5 key findings →
Participants: 302 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Exceeding the ambitions of the Sendai Framework for Disaster Risk Reduction 2015-2030, to switch the focus of DRR (Disaster Risk Reduction) solutions from top-down to people-centred approaches, requires a better understanding of the complexity and dynamics of citizen and stakeholder engagement in DRR processes. 1 key finding →
Participants: 51 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Neurodegenerative diseases such as Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and multiple sclerosis (MS), which are a consequence of the progressive loss of neuronal function and structure, cause significant cognitive impairment. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled.
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →